Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders.

Presented at the New Clinical Drug Evaluation Unit (NCDEU) annual meeting, June 12-15, 2006.

Theresa M. Winhusen, PhD (Cincinnati Addiction Research Center (CinARC), OV Node).

This presentation about CTN-0028 (Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders) describes the study's objectives, design, sites and participants, and primary outcome measures. It also offers an overall timelime for the project, as well as an update on the progress of Wave 1. (Presentation, PowerPoint slides, English, 2006)

Keywords: Adolescents | Attention Deficit Hyperactivity Disorder (ADHD) | CTN protocol development | Pharmacological therapy | Research design | New Clinical Drug Evaluation Unit (NCDEU) annual meeting, 2006

Document No: 125

Submitted by Theresa Winhusen, PhD, Co-Principal Investigator (6/16/2006).